Post Marketing Surveillance of MENOPUR

N/ACompletedNCT01202123

Ferring Pharmaceuticals2,501 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of highly purified (HP) menotrophine to Korean women.

Study Type

OBSERVATIONAL

Enrollment

2,501

Conditions

Infertility

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Anovulation in women (WHO group II) * Controlled ovarian hyperstimulation cases for ART Exclusion Criteria: * Hypersensitivity to MENOPUR * Pregnancy, lactation or contraindication to pregnancy * Ovarian cysts not related to polycystic ovarian syndrome * Abnormal uterine bleeding * Tumors in uterus, ovaries and breasts * Ovarian hyperstimulation syndrome * Thromboembolism or history of it * Infertile due to other reason than anovulation * High FSH level indication primary ovarian failure

Locations (19)

Busan Maria hospital

Busan, Busan, South Korea

Daegu Maria

Daegu, Daegu, South Korea

Outcomes

Primary Outcomes

Number of follicles per cycle

An ART cycle: From ovulation (number and size) to when chemical pregnancy test results are recorded

Time frame: Up to 6 weeks

Secondary Outcomes

Number of adverse events

An ART cycle: From ovulation (number and size) to when chemical pregnancy test results are recorded

Time frame: Up to 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.